INVA

Based on Innoviva, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does Innoviva do?

Innoviva develops and commercializes respiratory pharmaceuticals, primarily through a royalty and collaboration agreement with Glaxo Group Limited. Its approved products — BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA — target chronic obstructive pulmonary disease and asthma. The company earns revenue based on the commercial performance of these medicines rather than running its own large sales force.

Does INVA pay dividends?

Innoviva does not currently pay a dividend. The company's royalty-focused model means capital tends to be directed toward strategic investments and partnership activities rather than shareholder distributions. Income-focused investors should factor this into their assessment.

When does INVA report earnings?

Innoviva reports on a quarterly cadence, consistent with US-listed equities. Because our data source does not cover specific upcoming dates, investors should check Innoviva's official investor relations page for the most current earnings calendar.

Is INVA a good stock to buy?

UQS Score rates INVA as Good overall. The Attractive Valuation and Strong Risk pillar suggest a relatively stable, reasonably priced business. However, a Weak Moat and Neutral Growth profile indicate limited competitive insulation and modest expansion potential. The full pillar breakdown is available to Pro members.

Is INVA overvalued?

The UQS Valuation pillar rates INVA as Attractive, suggesting the stock is not considered expensive relative to its fundamentals. For a royalty-driven healthcare company with a stable but narrow revenue base, this may appeal to value-oriented investors. Full valuation metrics are accessible through a UQS Pro account.

How does INVA compare to its competitors?

Innoviva's royalty model — anchored by commercialized respiratory products — differs meaningfully from peers like MindMed, Oculis, and Ardelyx, which are either earlier-stage or focused on different therapeutic areas. This gives INVA a more predictable revenue profile, though with limited growth optionality compared to pipeline-driven peers.

What is INVA's market cap bracket?

Innoviva is classified as a small-cap stock. This places it in a segment of the market that can offer valuation opportunities but also carries liquidity and concentration risks that larger-cap healthcare companies typically do not face.

Who founded Innoviva?

The company was originally incorporated in 1996 as Theravance, Inc. before rebranding to Innoviva, Inc. in January 2016. Founding details are widely available through public corporate filings and the company's official history.

Is INVA a long-term quality investment?

As a long-term quality indicator, INVA's Good UQS Score reflects a mixed picture. The Strong Risk profile and Attractive Valuation support durability, but the Weak Moat and Neutral Growth suggest the business lacks the compounding characteristics typically associated with high-conviction long-term holdings. Pro members can view the complete analysis.

What is the main competitive advantage of Innoviva?

Innoviva's primary advantage lies in its established royalty agreements tied to three approved respiratory medicines distributed through GSK's global commercial network. However, the UQS Moat pillar rates this as Weak, reflecting the concentration risk and dependence on a single partner relationship rather than a broad, self-sustaining competitive position.

Innoviva, Inc. shows solid profitability with healthy returns on capital and reasonable margins.

Innoviva, Inc. shows steady but unspectacular growth, typical for mature companies.

Innoviva, Inc. carries minimal financial risk with conservative leverage and strong solvency.

Innoviva, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.

Innoviva, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for INVA.

The UQS (Unified Quality Score) for Innoviva, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Innoviva, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Innoviva, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.